This study is testing a new way to treat metastatic breast cancer, which is cancer that has spread from its original site. It uses a device called the Aliya™ Pulsed Electric Field (PEF) System. This system delivers short electrical pulses to shrink or destroy tumors. The main goal is to see how safe PEF ablation is for treating soft tissue tumors on the surface of the body. Researchers will also look at how it affects your symptoms and quality of life. You may be able to join if you have metastatic breast cancer with a soft tissue tumor that is at least 1 cm but no larger than 5 cm and can be easily reached. This study plans to enroll 20 participants, but its current recruitment status is unclear.

Study design

This is a single-arm study, meaning all participants receive the same treatment. It is a Phase I trial, focusing on safety, and plans to include 20 participants.

What's involved

You would receive a single treatment of PEF ablation to up to three soft metastatic breast cancer lesions. You will then have follow-up visits at Day 0, week 2, week 4, and up to 1 year after the treatment. You will also complete health-related and quality of life questionnaires.

Compensation

Not stated in the trial record.

Follow-up

Participants are followed for up to 1 year after the ablation treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.